NCT04557098: Phase 2- Teclistamab, in Participants With Relapsed or Refractory Myeloma (MajesTEC-1)
Updated: Oct 24, 2022
A Study of Teclistamab, in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-1)
Relapsed & Refractory Multiple Myeloma
The purpose of this study is evaluate the efficacy of teclistamab at the recommended Phase 2 dose (RP2D).
Study record NCT03145181 is Phase 1 part of this study and study record NCT04557098 is Phase 2 part of this study.
NCT03145181 - MajesTEC-1 - Parts 1-2
Phase 1 - Dose escalation study of teclistamab, a humanized BCMA*CD3 bispecific antibody, in participants with relapsed or refractory multiple myeloma (MajesTEC-1)
NCT04557098 - MajesTEC-1 - Part 3
Phase 2 - A study of teclistamab, a humanised BCMA x CD3 bispecific antibody in participants with relapsed or refractory multiple myeloma
Janssen Research & Development, LLC